ULBI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ultralife Corp (ULBI) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. While there is insider buying and slight revenue growth, the company's financial performance is weak, with significant net income and EPS declines. Additionally, technical indicators are neutral, and there are no strong trading signals or positive news catalysts to support immediate action.
The MACD histogram is positive at 0.0586 but contracting, indicating a lack of strong momentum. RSI is neutral at 55.478, and moving averages are converging, showing no clear trend. Key support is at 6.145, and resistance is at 7.098. The stock is trading near its pivot level of 6.622, suggesting indecision in price movement.
Insiders are buying, with a 315.93% increase in buying activity over the last month. Revenue increased by 10.56% YoY in Q4 2025.
No recent news or congress trading data to support positive sentiment. The stock has a 60% chance of minor negative performance in the next week (-0.74%).
In Q4 2025, revenue increased to $48,481,000 (up 10.56% YoY), but net income dropped to -$7,422,000 (down -3925.77% YoY), and EPS fell to -0.45 (down -4600.00% YoY). Gross margin improved slightly to 24.87% (up 2.90% YoY).
No analyst rating or price target data available for ULBI.
